<DOC>
	<DOCNO>NCT01106950</DOCNO>
	<brief_summary>This phase II therapeutic study relate donor HLA-haploidentical NK-cell base therapy high dose fludarabine/cyclophosphamide denileukin diftitox preparative regimen treatment poor prognosis acute myelogenous leukemia ( AML ) .</brief_summary>
	<brief_title>Haploidentical Natural Killer Cells Treat Refractory Relapsed Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Patients achieve complete remission neutrophil recovery ( ANC &gt; 500 ) least 4 week consider allogeneic transplant prolong remission ( independent study ) . All patient , include go transplant , follow determine disease free survival , treatment related mortality , time relapse .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>≥ 2 year age Meets one follow disease criterion : Primary acute myelogenous leukemia ( AML ) induction failure : complete remission ( CR ) 2 induction attempt Relapsed acute myelogenous leukemia ( AML ) : CR 1 cycle standard reinduction therapy . For patient &gt; 60 year age 1 cycle standard chemotherapy require either follow criterion meet : relapse within 6 month last chemotherapy blast count &lt; 30 % within 10 day start protocol therapy Secondary AML myelodysplastic syndrome ( MDS ) AML relapse &gt; 2 month transplant option donor lymphocyte infusion ( e.g . recipient autologous umbilical cord blood [ UCB ] transplant ) Patients prior central nervous system ( CNS ) involvement eligible provide treated CSF clear least 2 week magnetic resonance imaging ( MRI ) stable prior enrollment . CNS therapy ( chemotherapy radiation ) continue medically indicate study treatment . Available related HLAhaploidentical donor ( 35 6 HLAA , B C ) Karnofsky Performance Status &gt; 50 % Lansky Play score &gt; 50 Adequate organ function define : Creatinine : ≤ 2.0 mg/dL ( pediatric patient ClCr &gt; 50 ml/min age adjust Cr ) Hepatic : Liver function test ( LFT 's ) &lt; 5 x upper limit institutional normal ( ULN ) Pulmonary Function : oxygen saturation ≥ 90 % room air pulmonary function &gt; 50 % correct Diffusion lung capacity carbon monoxide ( DLCO ) Forced expiratory volume one second ( FEV1 ) Oxygen saturation [ &gt; 92 % ] use child pulmonary function test ( PFT 's ) obtain . ( Testing require symptomatic prior know impairment . ) Cardiac Function : Ejection fraction ( EF ) ≥ 40 % , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Able prednisone immunosuppressive medication least 3 day prior natural killer ( NK ) cell infusion ( exclude denileukin diftitox premeds ) Women child bear potential must negative pregnancy test within 14 day prior study registration agree use adequate birth control study treatment . Voluntary write consent Biphenotypic acute leukemia Transplant &lt; 60 day prior study enrollment New progressive pulmonary infiltrates screen chest xray chest computated tomography ( CT ) scan evaluate bronchoscopy , feasible . Infiltrates attribute infection must stable/improving ( associated clinical improvement ) 1 week appropriate therapy ( 4 week presume documented fungal infection ) . Surgical resection waif wait requirement . Uncontrolled bacterial viral infection chronic asymptomatic viral hepatitis allow Pleural effusion large enough detectable chest xray Known hypersensitivity study agent use Received investigational drug within 14 day enrollment Known active CNS involvement</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>primary acute myelogenous leukemia</keyword>
	<keyword>secondary acute myelogenous leukemia</keyword>
	<keyword>relapse acute myelogenous leukemia</keyword>
</DOC>